Skip to main content
Erschienen in: Wiener klinische Wochenschrift 7-8/2018

10.01.2018 | original article

Predictors of short-term LAMA ineffectiveness in treatment naïve patients with moderate to severe COPD

verfasst von: Vladimir Fijačko, MD, PhD, Marina Labor, MD, PhD, Mirjana Fijačko, Sanda Škrinjarić-Cincar, MD, PhD, Slavica Labor, MD, PhD, Iva Dumbović Dubravčić, MD, Tatjana Bačun, MD, PhD, Prof. Aleksandar Včev, MD, PhD, Prof. Sanja Popović-Grle, MD, PhD, Prof. Davor Plavec, MD, PhD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 7-8/2018

Einloggen, um Zugang zu erhalten

Summary

Background

No specific (only subgroup) recommendations for the use of long-acting muscarinic antagonists in chronic obstructive pulmonary disease (COPD) exist. The aim of this exploratory hypothesis generating study was to assess whether different phenotypic/endotypic characteristics could be determinants of the short-term ineffectiveness of the initial tiotropium bromide monotherapy in treatment naïve moderate to severe COPD patients.

Methods

A total of 51 consecutively recruited COPD patients were followed for 3 months after the initial evaluation and prescribed initial treatment (tiotropium). Short-term treatment ineffectiveness was assessed as a composite measure comprising COPD exacerbations, need for additional treatment, and no improvement in functional parameters, e.g. 6‑min walking test (6MWT), body-mass index, airflow obstruction, dyspnea, and exercise (BODE) index and forced expiratory volume in 1 s (FEV1), and as single components.

Results

Treatment ineffectiveness was significantly associated with baseline hemoglobin level, COPD assessment test (CAT) score, modified Medical Research Council (mMRC) scale and BODE index (p = 0.002). Incident exacerbation during the follow-up was associated with baseline bronchoalveolar lavage fluid (BALF) alpha-amylase level and CAT score (p < 0.001), and change in treatment with leukocyte count, 6MWT desaturation and fatigue (p < 0.001). No improvement in 6MWT was associated with baseline CAT score, body mass index, mMRC, fatigue, 6MWT and BODE index (p = 0.002). No improvement in BODE index was associated with leukocyte count, serum interleukin 8 (IL-8) and BALF albumin levels (p < 0.001); and no improvement in FEV1 with CAT score, baseline vital capacity and BALF tumor necrosis factor alpha (TNF-alpha) level (p < 0.001).

Conclusion

Our results suggest that there is a possibility to identify predictors of short-term tiotropium ineffectiveness in patients with moderate to severe COPD.
Literatur
1.
Zurück zum Zitat Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347–65.CrossRefPubMed Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347–65.CrossRefPubMed
3.
Zurück zum Zitat Bestal JC, Paule A, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the research council (MRC) dyspnea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54:581–6.CrossRef Bestal JC, Paule A, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the research council (MRC) dyspnea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54:581–6.CrossRef
4.
Zurück zum Zitat Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and validation of the COPD assessment test. Eur Respir J. 2009;34:648–54.CrossRefPubMed Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and validation of the COPD assessment test. Eur Respir J. 2009;34:648–54.CrossRefPubMed
5.
Zurück zum Zitat Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 2004;364:709–21.CrossRefPubMed Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 2004;364:709–21.CrossRefPubMed
6.
8.
Zurück zum Zitat Hogg JC, Chu F, Utokaparch S, Woods R, Elliot WM, Buzatu L, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Eng J Med. 2004;350:2645–53.CrossRef Hogg JC, Chu F, Utokaparch S, Woods R, Elliot WM, Buzatu L, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Eng J Med. 2004;350:2645–53.CrossRef
9.
Zurück zum Zitat Bathoorne E, Liesker JJ, Postma DS, Koëter GH, van der Toorn M, van der Heide S, et al. Change in inflammation in out-patient COPD patients from stable to a subsequent exacerbation. Int J Chron Obstruct Pulmon Dis. 2009;4:101–9.CrossRef Bathoorne E, Liesker JJ, Postma DS, Koëter GH, van der Toorn M, van der Heide S, et al. Change in inflammation in out-patient COPD patients from stable to a subsequent exacerbation. Int J Chron Obstruct Pulmon Dis. 2009;4:101–9.CrossRef
10.
Zurück zum Zitat Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev. 2004;56:515–48.CrossRefPubMed Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev. 2004;56:515–48.CrossRefPubMed
11.
Zurück zum Zitat Rachman I. Oxidative stress in pathogenesis of chronic obstructive pulmonary disease: cellular and molecular mechanisms. Cell Biochem Biophys. 2005;43:167–88.CrossRef Rachman I. Oxidative stress in pathogenesis of chronic obstructive pulmonary disease: cellular and molecular mechanisms. Cell Biochem Biophys. 2005;43:167–88.CrossRef
12.
Zurück zum Zitat Faganello MM, Tanni SE, Sanchez FF, Pelegrino NR, Luchet PA, Godoy I. BODE index and GOLD staging as predictors of 1‑year exacerbation risk in chronic obstructive pulmonary disease. Am J Med Sci. 2010;339:10–4.CrossRefPubMed Faganello MM, Tanni SE, Sanchez FF, Pelegrino NR, Luchet PA, Godoy I. BODE index and GOLD staging as predictors of 1‑year exacerbation risk in chronic obstructive pulmonary disease. Am J Med Sci. 2010;339:10–4.CrossRefPubMed
13.
Zurück zum Zitat Stockley RA, Mannino D, Barnes PJ. Burden and pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2009;6:524–6.CrossRefPubMed Stockley RA, Mannino D, Barnes PJ. Burden and pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2009;6:524–6.CrossRefPubMed
14.
Zurück zum Zitat Keam SJ, Keating GM. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Respir Med. 2004;3:247–68.CrossRefPubMed Keam SJ, Keating GM. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Respir Med. 2004;3:247–68.CrossRefPubMed
15.
Zurück zum Zitat Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium, Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146:545–55.CrossRef Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium, Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146:545–55.CrossRef
16.
Zurück zum Zitat Disse B, Speck GA, Rominger KL, Witek TJ, Hammer R Jr.. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive pulmonary disease. Life Sci. 1999;64:457–64.CrossRefPubMed Disse B, Speck GA, Rominger KL, Witek TJ, Hammer R Jr.. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive pulmonary disease. Life Sci. 1999;64:457–64.CrossRefPubMed
17.
Zurück zum Zitat Tashkin D, Celli B, Kesten S, Lystic T, Decramer M. Effect of tiotropium in men and women with COPD: results of the 4‑year UPLIFT trial. Respir Med. 2010;104:1495–504.CrossRefPubMed Tashkin D, Celli B, Kesten S, Lystic T, Decramer M. Effect of tiotropium in men and women with COPD: results of the 4‑year UPLIFT trial. Respir Med. 2010;104:1495–504.CrossRefPubMed
18.
Zurück zum Zitat Mamary Aj, Criner GJ. Tiotropium bromide for chronic obstructive pulmonary disease. Expert Rev Respir Med. 2009;3:211–20.CrossRefPubMed Mamary Aj, Criner GJ. Tiotropium bromide for chronic obstructive pulmonary disease. Expert Rev Respir Med. 2009;3:211–20.CrossRefPubMed
19.
Zurück zum Zitat Zeiger RS, Szefler SJ, Phillips BR, Schatz M, Martinez FD, Chinchilli VM, et al. Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol. 2006;117:45–52.CrossRefPubMed Zeiger RS, Szefler SJ, Phillips BR, Schatz M, Martinez FD, Chinchilli VM, et al. Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol. 2006;117:45–52.CrossRefPubMed
20.
Zurück zum Zitat Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34:648–54.CrossRefPubMed Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34:648–54.CrossRefPubMed
21.
Zurück zum Zitat Michielsen HJ, de Vries J, van Heck GL. Psychometric qualities of a brief self-rated fatigue measure: the Fatigue Assessment Scale. J Psychosom Res. 2003;54:345–52.CrossRefPubMed Michielsen HJ, de Vries J, van Heck GL. Psychometric qualities of a brief self-rated fatigue measure: the Fatigue Assessment Scale. J Psychosom Res. 2003;54:345–52.CrossRefPubMed
22.
Zurück zum Zitat Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005;26:319–38.CrossRefPubMed Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005;26:319–38.CrossRefPubMed
23.
Zurück zum Zitat Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J. 1993;6(Suppl 16):5–40.CrossRefPubMed Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J. 1993;6(Suppl 16):5–40.CrossRefPubMed
24.
Zurück zum Zitat Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, et al. Standardization of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005;26:720–35.CrossRefPubMed Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, et al. Standardization of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005;26:720–35.CrossRefPubMed
25.
Zurück zum Zitat American Thoracic Society, European Respiratory Society. ATS/ERS Recommendations for standardized procedures for online and offline measurement of exhaled lower respiratory and nasal nitric oxide. Am J Respir Crit Care Med. 2005;171:912–30.CrossRef American Thoracic Society, European Respiratory Society. ATS/ERS Recommendations for standardized procedures for online and offline measurement of exhaled lower respiratory and nasal nitric oxide. Am J Respir Crit Care Med. 2005;171:912–30.CrossRef
26.
Zurück zum Zitat ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111–7.CrossRef ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111–7.CrossRef
27.
Zurück zum Zitat Haslam PL, Baughman RP. Report or ERS task force: guidelines for measurement of a cellular components and standardization of BAL. Eur Respir J. 1999;14:245–8.CrossRefPubMed Haslam PL, Baughman RP. Report or ERS task force: guidelines for measurement of a cellular components and standardization of BAL. Eur Respir J. 1999;14:245–8.CrossRefPubMed
28.
Zurück zum Zitat Goossens LM, Leimer I, Metzdorf N, Becker K, Rutten-van Mölken MP. Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4‑year UPLIFT trial. BMC Pulm Med. 2014;14:163.CrossRefPubMedPubMedCentral Goossens LM, Leimer I, Metzdorf N, Becker K, Rutten-van Mölken MP. Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4‑year UPLIFT trial. BMC Pulm Med. 2014;14:163.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Miravitlles M, García-Sidro P, Fernández-Nistal A, Buendía MJ, de los Monteros MJE, Esquinas C, et al. The chronic obstructive pulmonary disease assessment test improves the predictive value of previous exacerbations for poor outcomes in COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:2571–9.CrossRefPubMedPubMedCentral Miravitlles M, García-Sidro P, Fernández-Nistal A, Buendía MJ, de los Monteros MJE, Esquinas C, et al. The chronic obstructive pulmonary disease assessment test improves the predictive value of previous exacerbations for poor outcomes in COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:2571–9.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat García-Sidro P, Naval E, Martinez Rivera C, Bonnin-Vilaplana M, Garcia-Rivero JL, Herrejón A, et al. The CAT (COPD Assessment Test) questionnaire as a predictor of the evolution of severe COPD exacerbations. Respir Med. 2015;109:1546–52.CrossRefPubMed García-Sidro P, Naval E, Martinez Rivera C, Bonnin-Vilaplana M, Garcia-Rivero JL, Herrejón A, et al. The CAT (COPD Assessment Test) questionnaire as a predictor of the evolution of severe COPD exacerbations. Respir Med. 2015;109:1546–52.CrossRefPubMed
31.
Zurück zum Zitat Karloh M, Fleig Mayer A, Maurici R, Pizzichini MM, Jones PW, Pizzichini E. The COPD assessment test: what do we know so far?: a systematic review and meta-analysis about clinical outcomes prediction and classification of patients into GOLD stages. Chest. 2016;149:413–25.CrossRefPubMed Karloh M, Fleig Mayer A, Maurici R, Pizzichini MM, Jones PW, Pizzichini E. The COPD assessment test: what do we know so far?: a systematic review and meta-analysis about clinical outcomes prediction and classification of patients into GOLD stages. Chest. 2016;149:413–25.CrossRefPubMed
32.
Zurück zum Zitat Kim S, Oh J, Kim Y‑I, Ban H‑J, Kwon Y‑S, Oh I‑J, et al. Differences in classification of COPD group using COPD assessment test (CAT) or modified Medical Research Council (mMRC) dyspnea scores: a cross-sectional analyses. BMC Pulm Med. 2013;13:35.CrossRefPubMedPubMedCentral Kim S, Oh J, Kim Y‑I, Ban H‑J, Kwon Y‑S, Oh I‑J, et al. Differences in classification of COPD group using COPD assessment test (CAT) or modified Medical Research Council (mMRC) dyspnea scores: a cross-sectional analyses. BMC Pulm Med. 2013;13:35.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, et al. Characterisation of COPB heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122.CrossRefPubMedPubMedCentral Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, et al. Characterisation of COPB heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Andrianopoulos V, Wouters EFM, Pinto-Plata VM, Vanfleteren LEGW, Bakke PS, Franssen FME, et al. Prognostic value of variables derived from the six-minute walk test in patients with COPD: Results from the ECLIPSE study. Respir Med. 2015;109:1138–46.CrossRefPubMed Andrianopoulos V, Wouters EFM, Pinto-Plata VM, Vanfleteren LEGW, Bakke PS, Franssen FME, et al. Prognostic value of variables derived from the six-minute walk test in patients with COPD: Results from the ECLIPSE study. Respir Med. 2015;109:1138–46.CrossRefPubMed
35.
Zurück zum Zitat Dal Negro RW, Tognella S, Bonadiman L, Turco P. Changes in blood hemoglobin and blood gases PaO2 and PaCO2 in severe COPD over a three-year telemonitored program of long-term oxygen treatment. Multidiscip Respir Med. 2012;7:15.CrossRef Dal Negro RW, Tognella S, Bonadiman L, Turco P. Changes in blood hemoglobin and blood gases PaO2 and PaCO2 in severe COPD over a three-year telemonitored program of long-term oxygen treatment. Multidiscip Respir Med. 2012;7:15.CrossRef
36.
Zurück zum Zitat Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol. 2009;4:435–59.CrossRefPubMed Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol. 2009;4:435–59.CrossRefPubMed
38.
Zurück zum Zitat Dickens J, Miller B, Edwards L, Silverman E, Lomas D, Tal-Singer R. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res. 2011;12:146.CrossRefPubMedPubMedCentral Dickens J, Miller B, Edwards L, Silverman E, Lomas D, Tal-Singer R. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res. 2011;12:146.CrossRefPubMedPubMedCentral
39.
40.
Zurück zum Zitat van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJ. A randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax. 2000;55:289–94.CrossRefPubMedPubMedCentral van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJ. A randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax. 2000;55:289–94.CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182:155–62.CrossRefPubMed Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182:155–62.CrossRefPubMed
42.
Zurück zum Zitat Hohlfeld JM, Sharma A, van Noord JA, Cornelissen PJ, Derom E, Towse L, et al. Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease. J Clin Pharmacol. 2014;54(4):405–14.CrossRefPubMed Hohlfeld JM, Sharma A, van Noord JA, Cornelissen PJ, Derom E, Towse L, et al. Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease. J Clin Pharmacol. 2014;54(4):405–14.CrossRefPubMed
Metadaten
Titel
Predictors of short-term LAMA ineffectiveness in treatment naïve patients with moderate to severe COPD
verfasst von
Vladimir Fijačko, MD, PhD
Marina Labor, MD, PhD
Mirjana Fijačko
Sanda Škrinjarić-Cincar, MD, PhD
Slavica Labor, MD, PhD
Iva Dumbović Dubravčić, MD
Tatjana Bačun, MD, PhD
Prof. Aleksandar Včev, MD, PhD
Prof. Sanja Popović-Grle, MD, PhD
Prof. Davor Plavec, MD, PhD
Publikationsdatum
10.01.2018
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 7-8/2018
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-017-1307-7

Weitere Artikel der Ausgabe 7-8/2018

Wiener klinische Wochenschrift 7-8/2018 Zur Ausgabe

mitteilungen der gesellschaft der ärzte in wien

Veranstaltungstipps

MUW researcher of the month

MUW researcher of the month